Inogen, Inc - Common Stock (INGN)

Inogen (NASDAQ:INGN) reported lower third-quarter revenue as weaker spending by large European customers offset a return to growth in U.S. sales. The respiratory care company also outlined a $20 million annualized cost-reduction program following the sale of its U.S. oxygen rental business. Revenue

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended September 30, 2026.

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that its Board of Directors has appointed Andy Reding, the Company’s Chief Operating Officer, as President and Chief Executive Officer and a member of the Board of Directors. Mr. Reding succeeds Kevin Smith.

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report third quarter 2026 financial results after the market closes on Thursday, November 5, 2026. On the same day, the Company will host a conference call at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time.

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it has signed a definitive agreement to divest its U.S. oxygen rental business to Rotech Healthcare, a leading national provider of home respiratory and medical equipment. Under the agreement, Rotech will acquire specified rental assets for a total estimated cash consideration of up to $25 million. The transaction is expected to close in the fourth quarter of 2026, subject to customary closing conditions.

International sales surged 14.8% as new product categories expanded the addressable market.

Inogen (NASDAQ:INGN) reported second-quarter 2026 revenue of $95.1 million, up 3% from a year earlier, as international growth, portable oxygen concentrator demand and contributions from newer products offset continued pressure in its U.S. direct-to-consumer business. The company lowered its full-y

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended June 30, 2026.

MKS Instruments director and former AWS executive to expand AI infrastructure firm’s stewardship

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report second quarter 2026 financial results after the market closes on Thursday, August 6, 2026. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET.

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Andy Reding to the newly created role of Chief Operating Officer, effective Monday, July 6, 2026. Mr. Reding will be responsible for driving revenue and operational performance, aligning cross-functional priorities, and helping ensure Inogen’s strategy is translated into efficient and measurable outcomes.

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended March 31, 2026 and reiterated its full-year guidance.

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report first quarter 2026 financial results after the market closes on Thursday, May 7, 2026. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET.

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Vafa Jamali as an independent director to the Inogen Board of Directors (the “Board”), effective on the date of the Company’s 2026 Annual Meeting, or June 15th if earlier.

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that Kevin Smith, President and Chief Executive Officer, will participate in a virtual fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026 at 10:15 a.m. Eastern Time.

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that the Compensation Committee of Inogen’s Board of Directors approved awards of restricted stock units as material inducement to Jason Richardson and Dominic Hulton entering into employment with the company to serve as its Chief Financial Officer and Chief Marketing Officer, respectively. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan.

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the following leadership appointments designed to accelerate the company’s next phase of growth.

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that Kevin Smith, President and Chief Executive Officer, will participate in a virtual fireside chat at the KeyBanc Virtual Life Sciences & MedTech Investor Forum on Tuesday, March 17, 2026 at 3:00 p.m. Eastern Time.

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the fourth quarter and the full year ended December 31, 2025 and provided 2026 guidance for the first quarter and full year.